 |
|
|
| |
Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With
HCV and HIV-1: The ASTRAL-5 Study
|
| |
| |
Reported by Jules Levin
EASL 2016 Barcelona April 14-17
David Wyles1, Norbert Brau2,3, Shyam Kottilil4, Eric Daar5, Kimberley Workowski6, Annie Luetkemeyer7, Oluwatoyin Adeyemi8, Peter Ruane9, Brian Doehle10, K.C. Huang10, Anu Osinusi10, John McNally10, Diana M. Brainard10, John G. McHutchison10, Susanna Naggie11, Mark Sulkowski12
1Division of Infectious Diseases, University of California, San Diego, California, USA; 2Veteran Affairs Medical Center, New York, New York, USA; 3Icahn School of Medicine at Mount Sinai, New York, New York, USA; 4Institute of Human Virology, University of Maryland, Baltimore, Maryland, USA; 5David Geffen School of Medicine, University of California, Los Angeles, California, USA; 6Emory University, Atlanta, Georgia, USA; 7University of California, San Francisco, California, USA; 8Rush University Medical Center, Chicago, Illinois, USA; 9Ruane Medical and Liver Health Institute, Los Angeles, California, USA; 10Gilead Sciences, Inc., Foster City, California, USA; 11Duke University, Durham, North Carolina, USA; 12Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
|
| |
|
|
|
|
|
